Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of the Philippines
With
Fresenius Kabi
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age: 18-65 years
Body weight: more than 40 kg
Trauma patients with onset of trauma ≤ 48h prior to assessment for inclusion in study, clinically judged to be in hemorrhagic shock by the attending surgeon and with 2 or more of the following characteristics:
* Penetrating or blunt etiology with hemodynamic instability at ER or intra-operatively
* Severely injured with Injury Severity Score (ISS) \> 15
* Hypotension defined as either ≥ 10mmHg change in SBP or MAP ≤ 65 mmHg or needing vasopressors (dopamine ≥ 5 mcg/kg/min or norepinephrine at any dose) at the time of admission/referral
* Hypoperfusion defined as base deficit ≥ 4 mmol/L
You may not be if
Known severe congestive heart failure (EF ≤ 35%)
Known chronic renal, liver or pancreatic disease
Known severe respiratory diseases e.g., TB, COPD, asthma
Known coagulopathy or bleeding tendency
Known allergy to Hydroxyethyl starch
Participation in a clinical drug trial within the last 2 months
Known Pregnancy or lactation
Severe traumatic brain injury GCS \< 9
Advanced cancer (stage IV or metastatic disease)
Patients receiving immunosuppressive drugs
Do-not-resuscitate status
Advanced directives restricting implementation of the protocol
Skeletal deformity, scarring, infection, gross contamination or previous surgery at the CVP insertion site
Severe hypoxemia if the CVP is to be inserted in the subclavian area
